Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 262

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 262
---
 in the market were discussed in addition to the unique position that OmnigenicsAI would have as a result of its two existing business units, Rewell and Heritas. The strategic vision was to create OmnigenicsAI as a part of a rebranding initiative for Heritas Argentina, separating it into two existing business units, integrating genomics and artificial intelligence, and establishing a new company poised for international growth through business development initiatives and potential mergers and acquisitions. Mr.Bransfield determined that, if he intended to pursue to the proposed transaction, he would purchase a SPAC and act as its sponsor. Mr.Bransfield elected to perform diligence on OmnigenicsAI in advance of such purchase. 122 Between February 21 and March 13, 2023, Union Acquisition Group, an entity controlled by Mr. Bransfield, conducted preliminary due diligence of OmnigenicsAI, obtaining access to balance sheets, financial information, funding history, research and development data base, as well as corporate information, to determine a preliminary valuation for OmnigenicsAI. At that time, Union Acquisition Group’s team started to review the comparable valuations in the private and public markets, including many notable precision medicine companies’ valuations and market potential, and reviewed an analysis on the current market competitors. During the week of March 20, 2023, Mr. Calmet held in -personmeetings with potential investors in Mexico, who were introduced by Mr. Bransfield, to discuss about the business combination opportunity and the development of the business in the Mexican market. The objective was, in addition to finding partners to build a wet -labin Mexico, to find strategic partners to scale OmnigenicsAI’s product portfolio. These investors and partners ranged from investment funds to laboratories. On April 20, 2023, Mr. Calmet had a call with Mr. Ramondt, Co -Founderand Chief Financial Officer of MultiplAI, whom he had previously met previously in October 2022, to discuss the businesses of OmnigenicsAI and MultiplAI. During that call, Messrs. Calmet and Ramondt discussed potential synergies between both companies and a potential business combination between OmnigenicsAI and MultiplAI. The idea of drafting a letter of intent (“LOI”) to pursue the deal was discussed. Subsequently, on April 24, 2023, Mr. Calmet shared with Mr. Bransfield notes of the MultiplAI meeting, which were later discussed in a